Polynovo Ltd (ASX: PNV) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Polynovo Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.68 billion
P/E Ratio 352.00
Dividend Yield 0.00%
Shares Outstanding 690.69 million
Earnings per share 0.008
Dividend per share N/A
Year To Date Return 41.99%
Earnings Yield 0.28%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Polynovo Ltd (ASX: PNV)
    Latest News

    Businessman smiles with arms outstretched after receiving good news.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was an absolutely delightful end to the trading week this Friday.

    Read more »

    A woman leaps into the air with loads of energy, in a lush green field.
    Share Market News

    Here are the top 10 ASX 200 shares today

    The ASX 200 had a Thursday to remember today.

    Read more »

    A woman sits in a cafe wearing a polka dotted shirt and holding a latte in one hand while reading something on a laptop that is sitting on the table in front of her
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a rough day for ASX 200 investors this Wednesday.

    Read more »

    A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
    Broker Notes

    3 ASX 200 shares just scored significant broker upgrades. Here's how

    The brokers’ bullish assessments for these ASX 200 shares include share price gains of up to 13%.

    Read more »

    Shot of a young scientist using a laptop while conducting research in a laboratory.
    Healthcare Shares

    2 popular ASX 200 healthcare shares tanking on earnings updates

    Let's check out the earnings reports from these two ASX 200 healthcare shares today.

    Read more »

    A neon sign says 'Top Ten'.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    The ASX 200 enjoyed another top day today, nearly breaking a record high.

    Read more »

    A neon sign says 'Top Ten'.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    The ASX 200 doubled up on the gains this Tuesday, giving investors another boost.

    Read more »

    Shot of a young scientist using a digital tablet while working in a lab.
    Healthcare Shares

    Up 10%: Why the Polynovo share price is popping today

    Polynovo shares are rocketing for the second day in a row...

    Read more »

    Smiling couple looking at a phone at a bargain opportunity.
    Share Gainers

    Why Boss Energy, Cooper Energy, Judo Capital, and Polynovo shares are racing higher

    These ASX shares are catching the eye of investors on Tuesday. But why>

    Read more »

    trophy depicting top 10, asx 200 shares
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a great start to the week for ASX shares today.

    Read more »

    The Two little girls smiling upside down on a bed.
    Small Cap Shares

    'Bright outlook': 2 ASX shares ready for a massive 2024 you've not thought about

    If you buy the same old big names as everyone else, it's pretty hard to outperform.

    Read more »

    The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was another hot day on the share market this Wednesday.

    Read more »

    Frequently Asked Questions

    The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was listed on the ASX  on 26 November 1998 and is headquartered in Melbourne.

    No, the company does not historically pay dividends.

    PNV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Polynovo Ltd

    PolyNovo Ltd (ASX: PNV) develops and commercialises innovative medical devices using its patented NovoSorb technology.

    NovoSorb is a family of biocompatible polymers that are used in the treatment of burns and surgical wounds. They biodegrade into by-products that can be absorbed and excreted by the body. For example, its NovoSorb BTM (Biodegradable Temporising Matrix) can be used to temporarily close a wound and aid the body in generating new tissue.

    PolyNovo’s products are sold across Australia and New Zealand, the United States, the United Kingdom, and Europe.

    PNV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    04 Oct 2024 $2.43 $-0.09 -3.57% 940,023 $2.49 $2.50 $2.43
    03 Oct 2024 $2.52 $-0.07 -2.70% 1,379,379 $2.59 $2.61 $2.47
    02 Oct 2024 $2.59 $-0.06 -2.26% 1,939,507 $2.60 $2.68 $2.58
    01 Oct 2024 $2.65 $0.04 1.53% 1,274,061 $2.60 $2.65 $2.58
    30 Sep 2024 $2.61 $-0.03 -1.14% 949,389 $2.63 $2.64 $2.57
    27 Sep 2024 $2.64 $-0.01 -0.38% 881,372 $2.62 $2.64 $2.58
    26 Sep 2024 $2.65 $0.09 3.52% 2,413,526 $2.57 $2.67 $2.56
    25 Sep 2024 $2.56 $0.01 0.39% 1,355,809 $2.55 $2.57 $2.52
    24 Sep 2024 $2.55 $0.06 2.41% 2,210,607 $2.48 $2.55 $2.48
    23 Sep 2024 $2.49 $0.03 1.22% 1,081,133 $2.39 $2.50 $2.39
    20 Sep 2024 $2.46 $0.00 0.00% 3,361,292 $2.49 $2.50 $2.42
    19 Sep 2024 $2.46 $-0.10 -3.91% 2,047,170 $2.56 $2.56 $2.46
    18 Sep 2024 $2.56 $-0.05 -1.92% 1,772,649 $2.59 $2.65 $2.55
    17 Sep 2024 $2.61 $0.16 6.53% 1,879,768 $2.50 $2.61 $2.48
    16 Sep 2024 $2.45 $-0.13 -5.04% 1,204,337 $2.59 $2.60 $2.45
    13 Sep 2024 $2.58 $0.04 1.57% 1,517,793 $2.56 $2.59 $2.53
    12 Sep 2024 $2.54 $0.12 4.96% 1,931,492 $2.50 $2.54 $2.43
    11 Sep 2024 $2.42 $-0.05 -2.02% 1,392,794 $2.48 $2.52 $2.40
    10 Sep 2024 $2.47 $0.12 5.11% 2,507,632 $2.38 $2.52 $2.38
    09 Sep 2024 $2.35 $0.02 0.86% 1,328,233 $2.27 $2.37 $2.27
    06 Sep 2024 $2.33 $0.03 1.30% 1,276,843 $2.29 $2.34 $2.27

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    30 Sep 2024 Andrew Lumsden Sell 50,000 $130,915
    On-market trade.
    26 Sep 2024 Leon Hoare Sell 100,000 $260,839
    On-market trade. As per announcement on 02-01-2024
    13 Sep 2024 Bruce Rathie Sell 750,000 $1,886,900
    On-market trade.
    31 Oct 2023 Robyn Elliott Buy 32,000 $38,080
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr David Williams Non-Executive DirectorNon-Executive Chairman Feb 2014
    Mr Williams is a director and investment banker with a track record in business development, mergers and acquisitions, and capital raising. He has experience advising companies in the food, medical device, and pharmaceutical sectors. Mr Williams is currently Managing Director of corporate advisory firm Kidder Williams.
    Dr Robyn Elliott Non-Executive Director Oct 2019
    Dr Elliott has a track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Her worldwide experience in new facility delivery, production scale up, strategy, regulatory affairs and audit will be invaluable to PolyNovo as the company scales its operations globally. Dr Elliott was Global Head, Strategic Portfolio Management at CSL Behring, a role that is responsible for governance oversight and business value delivery. Dr Elliott is a member of the Risk Committee.
    Mr Andrew Stuart Lumsden Non-Executive Director Jun 2021
    Mr Lumsden has more than 20 years of experience locally and internationally. Mr Lumsden is currently Chief Executive Officer of Wellcom Worldwide Australasia having previously held the roles of Group Chief Financial Officer and Group Chief Operating Officer. Prior to joining Wellcom, Mr Lumsden was a Senior Manager within the Audit and Assurance practice of PricewaterhouseCoopers. Mr Lumsden is the Chair of the Risk Committee.
    Mr Leon Hoare Non-Executive Director Jan 2016
    Mr Hoare has expertise across multiple Life Sciences sectors. He is currently the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously he was Managing Director of Smith & Nephew (S&N) ANZ. He served as President of S&N's Asia-Pacific Advanced Wound Management (AWM) businesses for 5 years and was a member of the Global Executive Management for the AWM Division.
    Ms Christine Emmanuel-Donnelly Non-Executive Director May 2020
    Ms Emmanuel-Donnelly is an IP and business development professional with more than 30 years of local and international experience. She has been on the Board of the Institute of Patent and Trademark Attorneys of Australia for over a decade. Ms Emmanuel-Donnelly was Executive Manager of Business Development and Commercial at the CSIRO, was in-house IP Counsel for Unilever in the U.K., and practiced as a patent and trademark attorney for Wilson Gunn.
    Mr Lior Harel Company SecretaryGeneral Counsel May 2024
    -
    Mr Swami Raote Chief Executive Officer Jul 2022
    -
    Swami Raote Chief Executive Officer
    -
    Jan Gielen Chief Financial Officer
    -
    Philip Scorgie Chief Information Officer
    -
    Joseph Amaral Chief Medical Officer (part-time)
    -
    Ingrid Anderson Chief People Officer
    -
    David McQuillan Chief Technical and Scientific Officer
    -
    Lior Harel Company SecretaryGeneral Counsel
    -
    David Morris President Asia Pacific
    -
    Edward Graubart President North America
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 96,149,727 13.93%
    J P Morgan Nominees Australia Pty Limited 80,078,534 11.60%
    Citicorp Nominees Pty Limited 37,720,578 5.46%
    Moggs Creek Pty Ltd (Moggs Creek Super A/C) 19,010,112 2.75%
    Lateral Innovations Pty Ltd (Trust A/C 10,924,103 1.58%
    Mr Anthony Shane Kittel Mrs Michele Therese Kittel (Kittel Family Super A/C) 8,050,000 1.17%
    Bnp Paribas Noms Pty Ltd 7,622,413 1.10%
    National Nominees Limited 6,653,041 0.96%
    Netwealth Investments Limited (Wrap Services A/C) 5,394,880 0.74%
    BNP Paribas Nominees Pty Ltd (IB AU Noms Retailclient) 4,533,452 0.66%
    BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 4,414,903 0.64%
    Commonwealth Scientific And Industrial Research Organisation 4,081,250 0.59%
    Mrs Li-Hsien Tsai 3,955,424 0.57%
    Mr David Kenley 3,755,000 0.54%
    Mr Paul Gerard Brennan 3,569,796 0.52%
    Mr Matthew James Avery 3,439,332 0.50%
    Mr David Kenley i 3,139,855 0.45%
    Dr Marcus James Dermot Wagstaff Mrs Lara Kate Wagstaff 3,072,166 0.45%
    Mr Evan Philip Clucas Ms Leanne Jane Weston (Kuranga Nursery Super A/C) 2,931,149 0.42%
    Mr Chris Dawborn (Haskali Super Fund A/C) 2,870,271 0.42%

    Profile

    since

    Note